RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW Investments has stepped in with $100 million to bankroll the launch.

Candel Therapeutics, Inc. CADL shares are down during Friday’s premarket session as the company announced the pricing of a public offering. The stock’s decline follows news that Candel intends to use ...

Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene besadenovec (CAN-2409) for intermediate- to ...

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash. Century has ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Director Paul B. Manning acquired 550,458 shares of Candel Therapeutics, Inc. NASDAQ:CADL common stock on February 23, 2026, at a price of $5.45, for a total transaction value of $2,999,996. The ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Candel Therapeutics shares were 15% lower, at $5.06, after the company priced an underwritten public offering of 18.3 million shares at $5.45 a share. The clinical-stage biopharmaceutical company said ...